Vesugen
A synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator family, studied for vascular endothelial bioregulation and cardiovascular geroprotection.
Also referenced as: KED, Lys-Glu-Asp
Also appears in: Longevity
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Cardiovascular. Also surfaces under Longevity for browsing and discovery.
KED, Lys-Glu-Asp
No FDA label signal · 1 trials · 362 PubMed results
Current evidence for Vesugen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Vesugen has no clinical trials that name it and 363 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Vesugen?
Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (KED), classified as a vascular-tissue bioregulator within the Khavinson peptide framework. It targets the endothelial lining of blood vessels and is theorized to support vascular integrity during aging.
How it works
- Endothelial gene regulation — proposed to modulate gene expression in vascular endothelial cells, supporting the production of structural and signaling proteins that maintain vessel wall integrity (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Vascular aging — endothelial dysfunction is a hallmark of cardiovascular aging; Vesugen is theorized to counteract age-related endothelial changes through epigenetic modulation
Research status
- Khavinson (2005) reviewed vascular applications of peptide bioregulators (Gerontology, 51(2):70–75)
- Khavinson et al. (2011) described short peptide-DNA interactions as the basis for tissue-specific bioregulation (Bulletin of Experimental Biology and Medicine, 152(1):102–105)
- No independent Western peer-reviewed clinical trials for Vesugen have been published
Key considerations
- Functionally related to Cardiogen (AEDR) — both target the cardiovascular system but Vesugen is focused on vasculature while Cardiogen targets cardiac muscle
- Part of the Khavinson bioregulator family with the same evidence limitations
- Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
- Often sold in cardiovascular-focused combination packs alongside Cardiogen